EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort

Mirosława Püsküllüoğlu, Anna Polakiewicz-Gilowska, Aleksandra Konieczna, Małgorzata Pieniążek, Justyna Żubrowska, Miloš Holánek, Renata Soumarová, Hana Študentová, Miroslava Malejčíková, Agnieszka Młodzińska, Karolina Winsko-Szczęsnowicz, Maja Lisik-Habib und 14 weitere

Supportive Care in Cancer · 2026-10 · 34 (10)

DOI: 10.1007/s00520-026-11274-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Supportive Care in Cancer, online erschienen am 28.09.2026. Verfasst von Mirosława Püsküllüoğlu und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland. miroslawa.puskulluoglu@krakow.nio.go…. Hauptthemen laut MEDLINE: Camptothecin, Granulocyte Colony-Stimulating Factor, Neutropenia, Triple Negative Breast Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Sacituzumab govitecan (SG) is a key treatment for metastatic triple-negative breast cancer (mTNBC). Neutropenia is a common toxicity, and the optimal use of G-CSF (primary prophylaxis versus reactive administration) remains uncertain. We evaluated the association of primary G-CSF prophylaxis with clinical outcomes and treatment-related toxicities. METHODS: We conducted a multinational retrospective real-world cohort study of 303 patients with mTNBC treated with SG in the second or a later line. Efficacy endpoints included progression-free survival (PFS) and overall survival (OS), analyzed using the Kaplan-Meier method. Adverse events were assessed according to CTCAE criteria. RESULTS: Of 303 patients, 100 were included in the primary prophylaxis group and 203 in the no primary prophylaxis group. Median PFS was 4.2 months in the primary prophylaxis group versus 5.1 months in the no primary prophylaxis group (p = 0.66), with 6-month PFS rates of 38.5% vs. 42.1%, respectively. Median OS was 10.9 vs. 11.6 months (p = 0.95), with 12-month OS rates of 44.9% vs. 47.1%. The frequencies of the recorded individual AEs were similar between groups, apart from grade 3-4 neutropenia, which was less frequent in the primary prophylaxis group (33.0% vs. 50.7%, p = 0.005). Febrile neutropenia occurred in 4.0% vs. 4.4% of patients (p = 1.00). Other recorded AEs (anemia, diarrhea, nausea, vomiting, alopecia) were comparable. Dose reductions due to toxicity were similar (36.0% vs. 38.4%, p = 0.71). In the no primary prophylaxis group, 74.4% subsequently received secondary G-CSF. CONCLUSIONS: In this retrospective real-world cohort, primary G-CSF prophylaxis was associated with a lower frequency of grade 3-4 neutropenia. No statistically significant differences in PFS, OS, or febrile neutropenia were observed between groups. These findings support a risk-adapted rather than universal approach to primary G-CSF prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CamptothecinGranulocyte Colony-Stimulating FactorNeutropeniaTriple Negative Breast NeoplasmsAdultAgedFemaleHumansMiddle AgedCohort StudiesKaplan-Meier EstimateProgression-Free SurvivalRetrospective StudiesSurvival Rate

Stichwörter der Autor:innen

G-CSFReal-world evidenceSacituzumab govitecanTriple-negative breast cancer

Substanzen

CamptothecinGranulocyte Colony-Stimulating Factor

Autor:innen und Institutionen

  • Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland. miroslawa.puskulluoglu@krakow.nio.gov.pl.
  • Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
  • Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Department of Oncology; Breast Unit Clinical Oncology Day Care Department, Wrocław Medical University, Wroclaw, Poland.
  • Lower Silesian Comprehensive Cancer Center, Wrocław, Poland.
  • Department of Clinical Oncology, Holy Cross Cancer Center, Kielce, Poland.

Zitieren

APA

Püsküllüoğlu, M., Polakiewicz-Gilowska, A., Konieczna, A., Pieniążek, M., Żubrowska, J., Holánek, M., Soumarová, R., Študentová, H., Malejčíková, M., Młodzińska, A., Winsko-Szczęsnowicz, K., Lisik-Habib, M., Pękala, A., Krejčí, D., Šustr, J., Kolářová, I., Danielewicz, I., Szymanik-Resko, M., Ciszewski, T., …, & Kubeczko, M. (2026). Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort. Supportive Care in Cancer, 34(10). https://doi.org/10.1007/s00520-026-11274-w

Vancouver

Püsküllüoğlu M, Polakiewicz-Gilowska A, Konieczna A, Pieniążek M, Żubrowska J, Holánek M, et al. Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort. Supportive Care in Cancer. 2026;34(10). doi:10.1007/s00520-026-11274-w

BibTeX
@article{Pskllolu2026,
  author = {Püsküllüoğlu, Mirosława and Polakiewicz-Gilowska, Anna and Konieczna, Aleksandra and Pieniążek, Małgorzata and Żubrowska, Justyna and Holánek, Miloš and Soumarová, Renata and Študentová, Hana and Malejčíková, Miroslava and Młodzińska, Agnieszka and Winsko-Szczęsnowicz, Karolina and Lisik-Habib, Maja and Pękala, Anika and Krejčí, Daniel and Šustr, Jan and Kolářová, Iveta and Danielewicz, Iwona and Szymanik-Resko, Magdalena and Ciszewski, Tomasz and Rušinová, Lenka and Czartoryska-Arłukowicz, Bogumiła and Łacko, Aleksandra and Pacholczak-Madej, Renata and Jarząb, Michał and Bielčiková, Zuzana and Kubeczko, Marcin},
  title = {Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {10},
  doi = {10.1007/s00520-026-11274-w}
}
Kostenlos starten →